T. Rowe Price Associates’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $36.4M | Buy |
|
|||||
|
2025
Q2 | $9.99M | Buy |
|
|||||
|
2025
Q1 | $8.39M | Buy |
|
|||||
|
2024
Q4 | $6.29M | Sell |
|
|||||
|
2024
Q3 | $8.1M | Buy |
|
|||||
|
2024
Q2 | $7.13M | Buy |
|
|||||
|
2024
Q1 | $7.95M | Sell |
|
|||||
|
2023
Q4 | $38.4M | Sell |
|
|||||
|
2023
Q3 | $54M | Sell |
|
|||||
|
2023
Q2 | $70.5M | Sell |
|
|||||
|
2023
Q1 | $89.2M | Sell |
|
|||||
|
2022
Q4 | $99M | Buy |
|
|||||
|
2022
Q3 | $94.1M | Sell |
|
|||||
|
2022
Q2 | $98.9M | Buy |
|
|||||
|
2022
Q1 | $88.1M | Sell |
|
|||||
|
2021
Q4 | $90.8M | Buy |
|
|||||
|
2021
Q3 | $79.4M | Sell |
|
|||||
|
2021
Q2 | $90.2M | Sell |
|
|||||
|
2021
Q1 | $103M | Sell |
|
|||||
|
2020
Q4 | $161M | Sell |
|
|||||
|
2020
Q3 | $346M | Buy |
|
|||||
|
2020
Q2 | $389M | Buy |
|